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Abstract

Strangles is a destructive disease in horses caused by an infection of the bacteria
Streptococcus equi subspecies equi. Current vaccines designed to protect horse
populations for this infection are only 50% effective at preventing the disease. The aim of
this study was to develop a vaccine against Streptococcus equi by targeting the
antiphagocytic virulence factor of the bacteria, the M-Protein (SeM18). SeM18 was
expressed using the ampicillin resistant pET vector system and purified by metal affinity
column using Cu(II). Purified protein was used to vaccinate chickens, and the antiSeM18 IgY present in the yolk of the eggs produced by these chickens was purified. IgY
was purified by SDS PAGE and Western Blot analysis. SDS PAGE of the induced
protein showed a distinct band at 18 kDa, indicating the presence of SeM18 in the
fraction. Analysis of the purified egg yolk detected the presence of anti-SeM18 IgY. This
IgY would then be used to vaccinate horses against Strep. equi infection.
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Investigations into the Use of the M-protein for the Production of a Vaccine Against
Streptococcus equi Subspecies equi Using Chicken IgY

Introduction
Etiology
Streptococcus equi subspecies equi is a Gram-positive bacterium of the
Lancefield’s group C. In vitro, it grows in long chains of irregularly shaped cocci, and its
colonies are an amber color and have the appearance of mucus. When isolated, it is
encapsulated and is highly virulent. Strep. equi causes hemolysis, which is the rupture of
red blood cells.
Pathogenesis
When this organism is inhaled or ingested by members of the family Equidae, the
cells attach to the tonsil and adjacent lymphoid nodules (Wilson, 1988). Enzymes and
toxins are then released by the bacteria that damage nearby cells and cause inflammation
of the affected area. The success of the bacterial infection is significantly aided by the
presence of the M-protein (SeM18) within the bacterial capsule of Strep. equi. Immune
cells, neutrophils and macrophages, in the host animal generally serve to protect it from
infection by phagocytizing foreign material such as bacteria. The M-protein released by
Strep. equi inhibits such phagocytosis. Opsonization is a process by which foreign
particles in the body are marked by the complement system that attracts phagocytes to
this particle to destroy it. The M-protein released by Strep. equi inhibits complement
deposition, thereby preventing opsonization (Boschwitz & Timoney, 1994).
Other factors released by Strep. equi that contribute to its virulence include
capsular hyaluronic acid, hemolysins, hyaluronidase, leukocytotoxins, and mitogens
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(Chanter, Collin, Mumford, 1994). The hyaluronic acid capsule and SeM18 also increase
the strength of this bacterial infection by helping the bacteria attach to host cells. The
bacteria move to the submandibular and retropharyngeal lymph nodes, and, even though
SeM18 has decreased the effectiveness of immune response in the host organism, many
neutrophils still migrate to these lymph nodes (Timoney, 2004). However, due to the
decreased ability of these neutrophils to phagocytize the bacteria as a result of SeM18’s
inhibition and the fact that the bacteria grow in chains, these neutrophils are ineffective in
clearing the infection and instead become a source of accumulation of dead cells in the
lymph nodes. The other sources of accumulation in the lymph nodes are necrotic tissue
and extracellular organisms. Usually, abscessing of lymphoid tissue only occurs in the
lymph nodes in the head and neck, but rarely this process will spread to other lymph
nodes throughout the body. Often the rupture of the retropharyngeal abscesses will leak
into the guttural pouch causing guttural pouch empyema, which is simply the
accumulation of puss and septic exudates in this area. This can cause swelling and pain in
the neck area and can even affect the horse’s breathing. Because Strep. equi infection
leads to constriction of the upper airway due to a number of different factors, it has also
been called “strangles” (Taylor & Wilson, 2006).
Epidemiology
Strangles was first described in 1888, though this condition that affects horses had
been referenced for centuries (Todd, 1910). Horses normally have bacteria growing in the
nasopharyngeal areas that are harmless to the animal and yet help to keep other more
dangerous infections from taking the horse by competition. These bacteria are called
normal flora, and while Streptococcus equi subspecies zooepidemicus is part of a horse’s
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normal flora, Strep. equi subspecies equi are not. Yearlings and young adult horses have
been found to be the most susceptible, with yearlings being most severely affected by the
bacterial infection (Sweeney, Whitlock, Meirs, 1987).
Overcrowding, mixing of horses from different areas, weaning, traveling, severe
weather, concurrent illness, and improper nutrition can lead to increased transmission of
the disease between horses (Reed, Bayly, Selon, 2004). This is because, after two to three
days of the infection, horses shed Strep. equi in nasal secretions. Therefore, any factor
that keeps horses in close contact with each other lends itself to increasing transmission
of bacterial infections. If the bacteria in the nasal secretions lands on feeders, water
bucks, tack, handlers, etc., and these items are then used for a different horse, this new
horse is likely to come into contact with this virulent bacterial infection. Once outside of
the horse’s upper respiratory tract, heat, sunlight, desiccation, and the many disinfectants
used on most well-managed farms, the organism does not survive for more than a few
weeks (Wilson, 1988).
Immunology
Because the innate immune response is so hindered by SeM18 and other
antiphagocytic factors released by the bacteria to increase the strength of the infection,
the most important protective immune response to Strep. equi is the specific immune
response.
Specific immune response. The specific immune response includes the
production of antibodies specifically designed by B cells to bind to specific antigens on
the bacteria and lead to their degradation. Undifferentiated B cells in the horse present
many different antibodies on their surfaces, and when one of these antibodies comes into
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contact with a protein on the bacteria that it precisely fits, this antibody/antigen complex
is taken up by the B cell and proteolyzed into peptides. These peptides, which have the
capability to produce an immune response, are presented on the surface of the B cell by
its MHC II molecules. The matching helper T cell is then attracted to the combination of
MHC and antigen, and it releases lymphokines and thereby activates the B cell. The B
cell then produces millions of copies of the antibody, which circulate in the blood and
lymph fluid. These antibodies bind to the antigens of the bacterial infection throughout
the body and mark them for destruction. Antibodies can be produced that are designed to
bind to the many different antigens on the surface of the bacteria. The most effective
antigen to target with production of specific antibodies has been shown to be the Mprotein (Timoney & Eggers, 1985).
Memory cells and the secondary response to infection. When B cells and T
cells are activated during the specific immune response, some of the proliferating cells
are selected to become memory cells. These memory cells contain antibodies for the
specific antigen in question, and when that antigen is subsequently encountered, the
memory cells mount a secondary immune response, which can give a stronger response
much more quickly. Following a natural infection of Strep. equi subspecies equi, 75% of
horses are able to mount an effective secondary response against future infection for four
years (Hamlen, Timoney, Bell, 1994). One special form of a secondary response occurs
when a foal is born to an immune mare. Strep. equi specific antibodies can be passed to
the newborn horse from a mother who has built up these antibodies. This results in
temporary immunity for the foals, but this phenomenon disappears after approximately
three months (Galan & Timoney, 1987).
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Clinical Signs
Clinical signs of a Strangles infection can be seen after three to eight days of
having come into contact with the bacteria. These symptoms include a fever of 103°106°F, anorexia, depression, and mucopurulent nasal discharge (Yelle, 1987). In the
effort to fight off the infection, the number of leukocytes in the blood of the horse
increases significantly, and this effect can be visualized when a sample of blood is taken
and observed under microscope. In addition, the lymph nodes swell with the increase in
production of lymph fluid to fight this bacterial infection. These lymph nodes abscess and
rupture, and the horse generally recovers in one to two weeks (Reed et al., 2004).

Figure 1 Medial retropharyngeal lymph node abscess visible in Viborg’s
triangle (Taylor & Wilson, 2006).
The major concern with Strangles infection is that the lymph nodes may become
large enough to press in against the walls of the upper respiratory tract and keep the horse
from breathing. If this is happening, the horse will often make a distinctive straining
noise when trying to breathe. A tracheotomy, which is a surgical procedure in which an
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incision is made in the front of the animal’s neck that connects directly to the trachea,
may need to be performed so that the horse does not asphyxiate.
Diagnosis
A definitive diagnosis can be made by a culture of nasal washes or fluid aspirated
from the abscessed lymph nodes.
Polymerase chain reaction. Polymerase Chain Reaction (PCR) is a molecular
biology technique that generates many copies of a particular DNA sequence for gene
sequencing, DNA-based phylogeny, or functional analysis of genes. PCR can accomplish
in a few hours what previously took weeks by inserting the target DNA into bacteria
vectors for amplification. PCR utilizes three steps: denaturation, annealing, and
elongation. Denaturation, which is the melting of the DNA sequence thereby taking away
its characteristic conformation and separating the two strands of the double helix, is
performed by heating the sequence to approximately 94 degrees Celsius. Annealing
occurs when a complementary primer strand binds by hydrogen bonds to the denatured
DNA strand as it cools to about 54 degrees. These primers are short segments of singlestranded nucleic acids that initiate synthesis. Because primers are highly specific and
initiate the production of DNA copies, the choice of appropriate primer is an extremely
important aspect of implementing the PCR technique.
The elongation step occurs when DNA polymerase attaches at the primers and
copies the DNA template in both directions using the bases adenosine, guanine, cytosine,
and thymine present in the PCR reaction mixture. PCR is performed in multiple cycles,
and each cycle doubles the number of DNA copies, resulting in exponential amplification
of the target DNA sequence. PCR has been used to identify the DNA sequence of the
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Strep. equi SeM18 gene, and is three times more sensitive in detecting Strep. equi than
culture (Timoney & Artiushin, 1997).
Enzyme-linked immunosorbent assay. Another important means of diagnosis
involves taking a sample of the horse’s blood and measuring serum levels of SeM18
antibody with an enzyme-linked immunosorbent assay (ELISA) test. An ELISA test
involves coating a surface with an unknown amount of antigen. The antibody for the
specific antigen in question is applied to the surface, and this antibody is linked to an
enzyme. When a substrate is added to the surface containing both antigen and antibody,
this will cause a visually noticeable change in the material, most often a color change. A
color change therefore indicates the presence of the antigen, in this case, SeM18
(Sheoran, Sponseller, Holmes, 1997). It is possible for a horse to come into contact with
Strep. equi and remain asymptomatic yet serve as carrier for the bacterial infection to
spread to other horses in its environment. For this reason, diagnostic testing of animals
that appear to be well is important to prevent the spread of this disease (Collins &
Wernery, 1999).
Treatment
Treatment for horses that have developed a Strep. equi infection has been a matter
of controversy. Most horses require only rest in a warm, dry setting with access to soft,
moist feed and fresh water, with nonsteroidal antiinflammatory drugs such as
pheylbutazone and flunixin meglumine to reduce fever and pain. However, antimicrobial
drugs can be used to treat the infection more effectively. With use of antimicrobial drugs
at the onset of fever and nasal discharge and the length of time to recover is reduced,
lymph node abscesses do not form. Procaine penicillin G at 22,00IU/kg twice per day for
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ten to fourteen days is the standard prescription (Wilson, 1988). If lymph abscesses
develop, they should be lanced and drained daily until they return to normal size. To
prevent Strep. equi infection from occurring, three vaccines are available. Unfortunately,
vaccines only effectively protect 50% of Strangles cases from occurring.
Vaccines and the secondary response. Vaccines are an important
immunological tool for the prevention of disease. The idea behind a vaccine is the
secondary response of the animal immune system. When an animal has been exposed to a
bacteria or virus in the past, its immune system contains memory cells that “remember”
the specific biochemistry of that foreign particle. These memory B cells and T cells can
more quickly respond to a second infection and eliminate it before substantial symptoms
are perceived. A vaccine contains a virus or bacteria and exposes the animal to it, so it
can have an appropriate secondary response when it comes into contact with the virus or
bacteria in nature. A vaccine can be an attenuated, which means that it is a weakened
form of the bacteria or virus. A vaccine may contain a dead virus or bacteria. A vaccine
may contain the most antigenic parts of the virus or bacteria but not the whole organism.
If the animal were injected with a simple culture of the Strep. equi bacteria, it would
succumb to infection, and a problem would have been created rather than prevented. By
exposing the animal’s immune cells to a non-dangerous form of the bacteria, it is able to
mount a response when they encounter that antigen again in its virulent form.
The strangles vaccine. The most effective Strangles vaccine involves injecting
the animal with a low concentration of the SeM18 protein so that when it encounters the
complete Strep. equi bacteria, it is able to recognize the SeM18 protein and respond much
more strongly and quickly to prevent infection (Hoffman, Staempfli, & Prescott, 1991).
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These vaccines are administered intramuscularly. Administration of vaccines with
bacterial extracts has been shown to cause purpura hemorrhagica, an immune-mediated,
type III hypersensitivity, and high concentrations of SeM18 increase the risk for this
reaction. (Pusterla, 2003)
Developing an effective vaccine for Strep. equi is currently a matter of much
research, as the most effective vaccine is only 50% effective. Because Strep. equi shares
greater than 95% DNA homology with Streptococcus zooepidemicus, another less
virulent beta-hemolytic Streptococcus, many of the proteins produced by the two bacteria
are identical. Interestingly, however, the immune response to Strep. zooepidemicus does
not protect the animal from Strep. equi infection (Bazeley, 1942). For this reason, in
order to develop an effective vaccine against Strep. equi, those proteins that are
immunoreactive and are not shared by these two bacterial strains should be investigated
as to their use in a vaccine. The proteins that have been shown to be expressed by Strep.
equi but not Strep. zooepidemicus include Se18.9, SeM18, SePE-H, and SePE-I (Tiwari,
Quin, Artiushin, Timoney, 2007). Interestingly, there is an allele for the SeM18 protein in
Strep. zooepidimicus, but it is not expressed (Timoney, Artiushin, Boschwitz, 1997).
In the process of developing a vaccine, inactivated whole bacteria and several
recombinant proteins have been used, but with little success. Vaccines using attenuated
whole bacteria have conferred immunity to an insignificant number of horses, and more
often induced adverse reactions (Jorm, 1990). Several mouse studies indicated that
vaccines targeting the SeM18 protein of Strep. equi effectively cause generation of
SeM18 reactive antibodies in the animal. However, vaccines specifically targeting
SeM18 have had little success in protecting horses. One study found that “lack of
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efficacy of vaccines is probably not due to failure to stimulate serum bactericidal
antibodies but failure to stimulate pharyngeal antibodies to the Strep. equi M protein”
(Galan & Timoney, 1987). Several mouse studies also indicated that a recombinant
hyaluronate associated protein (HAP) caused the generation of protective antibodies
against this protein but likewise did not protect vaccinated horses from developing
strangles (Chanter, et al., 1999). These mysterious results imply that a vaccine with
multiple recombinant proteins may be necessary so that multiple immune responses can
be mounted to clear the bacteria.
One intranasal vaccine, the “Pinnacle I.N.”, developed by Timoney, is of
particular interest. A non-specifically attenuated strain of Strep. equi was developed by
chemical mutagenesis that resulted in non-defined point mutations throughout the
genome. After being injected into the animal, back mutations can occur and bring the
bacteria up to full virulence. This vaccine has not been licensed due to safety concerns,
despite the fact that it may protect up to 100% of horses (Timoney, 1993). In an attempt
to improve the safety of this vaccine, deletions of the 3’ end of hasA gene and the 5’ end
of the hasB gene were performed, making this bacterial mutant unable to reverse to full
virulence. Studies have been inconclusive as to whether these deletions make the vaccine
safer for horses.
Another important landmark in the development of an effective Strangles vaccine
is the live attenuated strain TW 928 developed by Intervet. The aroA gene was deleted
from this bacterial strain, resulting in a 104-fold decrease in virulence in mouse studies.
When horses were intramuscularly vaccinated, they had 100% protection from future
Strep. equi infection, but severe adverse reactions occurred, which made further use of
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this vaccine impossible. Lower concentrations of the TW 928 strain were used, and while
the decreased concentration decreased adverse reactions, it also decreased the protection
conferred by the vaccine. Small collections of pus developed in the top layers of the skin
at the site of injection, and these pustules contained the TW 928 strain. With decreased
concentrations of TW 928 in the vaccine, less pustules formed and less protection was
offered. With increased concentrations of TW 928 in the vaccine, more pustules formed
and more protection was offered. These results suggest that the pustules play a significant
role in the generation of an immune response against Strep. equi (Jacobs, Goonerts,
Nuijten, Hartford, & Foster, 2000).
Though live attenuated vaccines may provide the best protection, multicomponent subunit vaccines based on several immunogenic Strep. equi surface proteins
remain the vaccines of choice in current veterinary practice. This is because of the severe
adverse effects experienced by a significant number of horses vaccinated with the live
attenuated bacterial strains. By combining the protective effects of inoculating with
recombinant proteins, increased protection can be conferred to the animal without the
level of adverse effects experienced with live attenuated bacterial strains (Flock,
Karlstrom, Lannergard, & Guss, 2006).
IgY for the Development of Effective Vaccines
On the frontier of research in vaccine development is the use of Immunoglobin Y
from egg yolk to confer immunity. When an egg is produced in the ovary,
immunoglobins from the hen are transferred to the yolk at a concentration of 6-13 mg/ml,
comparable to the concentration of IgY in the hen’s serum. IgY is phylogentically similar
to mammalian IgG and IgE, but its structure is significantly different (Wart, Magor,
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Higgins, 1995). In this case, the M protein from Strep. equi could be injected into a hen,
and this hen’s immune system would produce antibodies against this bacteria. When this
hen lays eggs, it will passively immunize each egg by transferring anti-Strep. equi IgY
antibodies to the yolk of each egg. IgY from collected eggs can be purified and
administered orally or otherwise to a horse to protect it against Strep. equi.
Advantages of IgY. Chicken antibodies are preferable to mammalian antibodies
for research and immunotherapeutic purposes for several reasons. First, eggs are a much
more efficient way of collecting large amounts of antibodies. It is much easier to make a
chicken lay an egg than it is to bleed a mouse, goat, or rabbit. Hens produce five to six
eggs per week, which results in a concentration of antibodies equivalent to 75 to 90 ml of
serum. It would take an immunized rabbit three to five weeks to produce that same
amount and would also involve pain for the animal. In addition, the cost of caring for a
chicken is much less than that of caring for a rabbit (Rollier, Charollois, Jamard, Trepo,
Cova, 2000). A second benefit of the use of chicken antibodies is the phylogenetic
distance between avian antibodies and mammalian antigens. Because the proteins that a
chicken contains in its body and that it comes into contact with in its environment are
significantly different than the proteins that a mammal contains in its body and that it
comes to into contact with in its environment, chickens recognize many more of the
antigens on the Strep. equi as foreign and can therefore mount a stronger response to
eliminate the infection. More antibodies bind to the molecule, amplifying the immune
response.
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Figure 2
Comparison of chicken IgY with mammalian IgG, showing the significant
structural differences between the two which make chicken IgY preferable to IgG for use
in vaccine development (Tini, Jewell, Camenisch, Chilov, Gassmann, 2002).
A third benefit of the use of chicken antibodies is that it reduces intereference.
Chicken IgY do not cross react with mammalian IgG and therefore avoid interference due
to rheumatoid factors (Tini et al., 2002). In addition, chicken antibodies to not activate
the human complement system. A fourth benefit of the use of chicken antibodies is that
they are incredibly stable. They can be stored for over ten years at four degrees Celcius
without loss of antibody activity or for over six months at room temperature. IgY can
withstand pH 4-9 (Lee, Chang, Lee, Lee, Koo, 2002). IgY has been administered orally to
prevent and treat a variety of diseases, including rotavirus in mice, human rotavirus,
bovine coronavirus, entertotoxigenic E. coli in pigs, Salmonella species in mice,
Helobacter pylori, Streptococcus mutans, and Pseudomonas aeruginosa for treatment of
Cystic fibrosis in humans (Zhang, 2003).
Premise for Study
The aim of this study was to develop a vaccine against Streptococcus equi. This
particular vaccine targeted the antiphagocytic protein SeM18, which makes substantial
contributions to the virulence of the Streptococcus equi bacterial infection and is unique
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to this bacteria. I describe in this paper the characterization of SeM18 and the cloning and
expression of its structural gene in Escherichia coli. For this procedure, the pET system
was used, which is a powerful system for the cloning and expression of recombinant
proteins in E. coli. I describe the purification of SeM18 from the induced culture and its
inoculation into a hen for the production of antibodies. I describe the purification of the
resulting IgY and its potential use as vaccine against Streptococcus equi.
Methods and Materials
Expression of the M-protein
In order to express the SeM18 protein, it was necessary to grow a starter culture
of the pET recombinant in a λDE3 lysogen. The pET recombinant protein was provided
by Sergey Artiushin from the Gluck Equine Research Center at the Department of
Veterinary Science of the University of Kentucky. To prepare the pET system, the target
gene that programs the SeM18 protein was cloned in pET plasmids using bacteriophage
T7 transcription signals. The target protein was established in a non-expression host, then
the plasmid was transferred into an expression host containing a chromosomal copy of
the T7 RNA polymerase gene under lacUV5 control. The plasmids contained a T7lac
promoter, which is a lac operator sequence just downstream of the T7 promoter. This
provided safety for the E.coli because the target gene product may have interfered with
normal cell function and therefore inhibit its ability to produce mass quantities of the
protein. The source used in this experiment to induce was Isopropyl β-D-1thiogalactopyranoside (IPTG).
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Figure 3

The pET-15b vector used to culture and express SeM18.

From a glycerol stock of the E. coli with the SeM18 protein gene already
established, 20µL was transferred to an agar plate, having been prepared with Luria Agar
from Sigma-Aldrich and a 1M concentration of ampicillin. Ampicllin was used because
the pET vector system was designed to be amp-resistant. Therefore, only the E. coli
containing the recombinant protein should have grown because virtually no other bacteria
present in the lab environment could be amp-resistant. The Luria agar plate was
incubated for 24 hours at 37°C to allow ample time for the bacteria to grow. Three
colonies were selected and transferred to three 3mL culture tubes containing Lurai Broth
from Sigma-Aldrich containing 1M ampicillin. The cultures were incubated in the
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shaking incubator until the bacterial growth reached an OD600 of 0.6, a process which
took approximately five hours. The entire contents of these culture tubes were each then
transferred to a flask containing 100mL Luria Broth with ampicillin. These flasks were
then incubated at 37°C with shaking until the bacterial growth reached an OD600 of 0.6,
which took approximately three hours. To these cultures, 100µL of 1M IPTG was added
and continued to incubate at 37°C with shaking overnight. The IPTG induced culture was
centrifuged at 14,000 x g for thirty minutes. A sample of the supernatant was kept for
comparison on SDS PAGE, and the rest discarded.
Purification of M-protein with Metal Affinity Column
The pellet was resuspended in 1/20 the volume of Buffer A (8M urea, 20mM
TRIS, 100mM NaCl, pH 8.0) of the initial culture, which was about 4.8mL. The Buffer
contained 8M urea in order to break up the inclusion bodies. To disrupt the cells, the
solution was frozen in the -80°C freezer for thirty minutes and then allowed to thaw.
Viscosity was reduced by passing the solution through a syringe needle several times. In
order to pellet cell debris, the mixture was then centrifuged at 14,000 x g for thirty
minutes. The pellet was saved for comparison on SDS PAGE. The supernatant from this
centrifugation was loaded onto a metal affinity column.
The column was prepared using a His-binding resin because the pET vector
system contained a His-tag. Using a 1x8cm column, the slurry was poured and allowed to
settle. The column was filled with buffer A several times to wash the column thoroughly.
The buffer A was drained to a level just slightly above the gel top, at which point 0.5mL
of 0.1 M CuSO4 solution was added to the column and allowed to enter. Buffer A was
then added to the column to wash the column thoroughly until all excess Cu(II) had been
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eluted, which required about 25mL. After buffer A had drained to a level just at the top of
the gel, approximately 4mL of the supernatant containing the recombinant protein was
added to the top of the gel and allowed to enter. 5mL fractions were collected from this
point. The column was filled with buffer A to elute all unwanted proteins and
nucleotides. A280 measurements were taken of each fraction by transferring the contents
of each fraction into a quartz cuvette and measured by Genesys spectrophotometer. When
the measurements neared 0.000 absorbance, the column was washed with buffer B (8M
urea, 20mM TRIS, 100mM NaCl, 100mM Imidazole, pH 8.0). 1mL fractions were
collected and A280 measurements taken with the spectrophotometer in a quartz cuvette.
SDS PAGE Analysis
The most concentrated of both the wash fractions and the elution fractions were
prepared to be applied to an SDS PAGE gel. The original induced culture in LB broth,
the original supernatant from the first centrifugation, the second pellet from the second
centrifugation, the wash fraction that gave the highest absorbance, the elution fraction
that gave the highest absorbance, and a molecular weight standard were prepared for SDS
PAGE. 15µL of each were transferred to seven different 1.5mL eppendorf tubes. To each
tube excluding the molecular weight standard, 15µL Sample Buffer (0.5 M Tris-HCl
pH6.7, 20% SDS, 20mL glycerol, a pinch of Bromphenol Blue, and 0.5mL Betamercaptoethanol) were added. The tubes were boiled for five minutes, microcentrifuged
for thirty seconds, and transferred to the gel. The gel used was 4-20% poly-acrylamide
from Bio-Rad. The SDS PAGE apparatus was from Bio-Rad. The Electrophoresis Buffer
(3M Tris Base, 14.4M glycine, 1M sodium dodecyl sulfate) filled the inner and outer
chambers and was used to wash each lane of the gel. The gel was run at 200V until the
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lanes reached the end of the gel, which was approximately forty minutes. The gel was
then stained for one hour with coomassie blue stain, following which it was destained
with a methanol and 10% acetic acid destain overnight. Pictures of the gel were then
taken with a gel camera.
Production of Chicken Antibodies
A 500 µg/mL concentration of stock SeM18 protein was prepared and used to
immunize one chicken. The eggs collected from this hen were used to isolate IgY
designed for the SeM18 protein.
Isolation of IgY from Egg Yolk
Purification of IgY. The yolk was separated from the egg without breaking the
yolk and was mixed with three parts 0.1M Phosphate Buffered Saline (PBS) pH 7.5 and
one part17.5% polyethylene glycol (6000 MW), giving a final concentration of 3.5%
PEG. This mixture was stirred for twenty minutes at room temperature. The sample was
centrifuged at 3000 rpm for twenty-five minutes. The supernatant was removed and
poured through a cheesecloth to remove any residual yolk lipids and granules. Two parts
17% PEG was added to the one part supernatant and stirred for one hour in an ice bath to
precipitate the IgY. The cold was used to keep proteins from being denatured while
precipitating. The solution was then centrifuged for twenty-five minutes at 3000 rpm. The
supernatant was kept for later testing, and the IgY in the pellet was dissolved in an equal
volume of PBS.
SDS PAGE of IgY. An SDS PAGE gel was run using the same procedure as that
run with fractions from the metal affinity column. The culture supernatant, Triton-X 100
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extract, glass bead treated cells, and cell pellet were run alongside a molecular weight
standard.
Western blot of IgY. The proteins were transferred to a nitrocellulose membrane
where they were detected using antibodies specific to the target SeM18 protein. The gel
from the SDS PAGE was placed in Transfer Buffer (3.03 g Tris, 14.4 g Glycine, 20% v/v
methanol, 1L deionized water, pH 8.3) to equilibrate for fifteen minutes. The fiber pads
and filter paper were soaked in transfer buffer. A fiber pad was placed on the black side
of the Western Blot cassette, followed by a piece of filter paper and then the gel. The
wetted nitrocellulose membrane was laid over the gel, making sure that no air bubbles
were present between the gel and the membrane. Another sheet of wetted filter paper was
placed on the membrane followed by another fiber pad. The sandwich was closed and
placed in the electrophoresis module. This entire apparatus was placed in the tank, filled
with transfer buffer, and the unit was run overnight at 30V, constant 90mA. Anti-IgY
antibodies was applied to the filter paper to detect the presence of anti-SeM18 antibody
from the egg yolk.
Results
Expression of the M-protein
The bacterial colonies of the pET vector grew at 37°C. The colonies were an offwhite color and a circular shape, characteristic of Streptococcus growth on Luria Agar.
The agar was infused with ampicillin, a powerful antibiotic. Therefore, only the ampresistant E. coli used as the vector for the SeM18 protein should have grown. As there
was only one kind of colony, it was determined that they were, in fact, the E. coli of
interest. Approximately five hours was required to grow the 3mL culture tube to an
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OD600 of 0.6; approximately two and a half hours was required to grow the 100mL
culture flasks to an OD600 of 0.6.
Purification of M-protein with Metal Affinity Column
The His-Tag in the resin effectively bound SeM18, as shown by the fact that
switching to the elution buffer caused the release of a significant amount of protein. The
initial washing of the column gave very high concentration of material. Some of this may
include nucleotides as well as unwanted protein. (Figure 4) The elution with buffer B
showed significant concentration of protein that had not been collected using buffer A,
which indicates that it had bound to the metal affinity column and was likely SeM18.
High concentration of SeM18 in the early fractions tapered off to essentially zero
absorbance. (Figure 5)

Figure 4 (a) Absorption values obtained from the wash fractions using buffer A. (b)
Graphical representation of absorption values at OD280. High concentrations tapered off
to essentially zero absorption before switching to the elution buffer.
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Figure 5 (a) Absorption values obtained from the elution fractions using buffer B. (b)
Graphical representation of absorption values at OD280. High concentrations tapered off
to essentially zero absorption.
SDS PAGE Analysis
SDS Page analysis resulted in the presence of a band at the 18 kDa molecular
weight standard measuring point. This was the expected molecular weight for the
fragment of SeM18 being used in this study. The appearance of this distinct band was
taken as proof of the presence of this SeM18 fragment in the purified protein sample
(Figure 6).
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Figure 6 Digital image of the SDS PAGE gel after staining. From left to right:
Lane 1 contained the original supernatant from the centrifugation of the induced culture,
Lane 2 contained the induced culture in LB broth, Lane 3 contained the second pellet
from the centrifugation of the lysed cells, Lane 4 contained the second supernatant before
being applied to the column, Lane 5 was blank, Lane 6 contained the highest
concentration of the unwanted protein fractions, Lane 7 was blank, Lane 8 contained the
molecular weight standard, Lane 9 was blank, and Lane 10 contained the highest
concentration of the eluted SeM18.
Production and Isolation of Anti-SeM18 IgY
The resulting Western Blot showed bands corresponding to the 18kDa molecular
weight standard, which indicates the presence of the SeM18 protein. It was expected to
see a band in the lane that contained the stock protein as well as the lane that contained
the eluted protein. In the lane that contained the stock protein, there is a band at the
18kDa mark, but there is also a lot of protein at higher molecular weight marks. This may
mean that the stock had degraded due to experimental conditions. It may also mean that
the stock had been contaminated with other proteins due to improper storage. However, it
can be accepted that when the stock was used in previous experiments it did contain the
SeM18 protein in adequate amounts because it was successfully eluted from the metal
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affinity column and resulted in the production of anti-SeM18 IgY. In the lane that
contained the eluted protein, the darkest band corresponded to the 18kDa molecular
marker. This indicates that SeM18 was successfully produced by the pET vector and
isolated from the bacteria. It was expected that the lane containing the molecular weight
standard would not show up on the Western Blot because IgY should not have bound to
it. This was, in fact, the case. It was expected that the lane containing the IgY would
show up on the Western Blot, since the secondary antibody was anti-IgY. The molecular
weights were not expected to be at 18kDa, because the light and heavy chains of IgY are
not 18kDa, but of greater molecular weight. The fact that a band was visible in the IgY
lane that corresponds to 18kDa is therefore puzzling. This may mean that the IgY had
somehow already bound SeM18 during the experiment (Figure 7). Overall, the Western
Blot indicated that anti-SeM18 IgY was successfully produced.

Figure 7 Digital image of Western Blot after development. From Left to Right: Lane 2
contained the stock SeM18 protein, Lane 4 contained the molecular weight standard,
Lane 6 contained the highest fraction of the eluted SeM18 protein, and Lane 9 contained
the IgY produced by inoculated chickens against SeM18.
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Discussion
These results indicate that SeM18 was successfully expressed and is present in the
final protein fraction to be used to vaccinate horses for the prevention of Streptococcus
equi subspecies equi. The next step for the continuation of this study would be to
inoculate horses and test for the efficacy of this vaccine to prevent Strep. equi infection.
It would be advantageous to add protein fragments of several of the other immunogenic
proteins secreted by Strep. equi to increase the strength of the secondary response when
the horse encounters this bacteria in its environment. These include Se18.9, SePE-H, and
SePE-I. This procedure for producing anti-SeM18 IgY will be adopted by the Liberty
University Immunology class curriculum.
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